Evaluation and comparison of expectant treatment and drug treatment on retained products of concepton

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20240514061800N3

Enrollment

124

Registered

2024-08-20

Start date

2024-09-22

Completion date

Unknown

Last updated

2024-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Abortion. Complications following ectopic and molar pregnancy

Interventions

Intervention 1: Intervention group: They are treated with medication (600 micrograms of misoprostol administered sublingually). Intervention 2: Intervention group: They undergo expectant treatment.

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Patients with no history of previous abortion Patients without underlying disease Patients who have informed consent to participate in the study

Exclusion criteria

Exclusion criteria: Patients with a history of previous abortion Patients with underlying disease Patients who do not have informed consent to participate in the study

Design outcomes

Primary

Measure	Time frame
Improvement of menstrual intervals. Timepoint: Every 2 weeks for a maximum of 6 weeks. Method of measurement: Using an ultrasound scan.;Improvement of vaginal bleeding. Timepoint: Every 2 weeks for a maximum of 6 weeks. Method of measurement: Using an ultrasound scan.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactSepideh Ashrafi Vand

Shahid Beheshti University of Medical Sciences

sashrafivand@yahoo.com+98 21 23871

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026